In World journal of gastroenterology ; h5-index 103.0
There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.
Liu Xin-Yu, Tang Hao, Zhou Qing-Yang, Zeng Yan-Lin, Chen Dan, Xu Hui, Li Yue, Tan Bei, Qian Jia-Ming
2023-Jan-14
Artificial intelligence, Inflammatory bowel diseases, Multiomics, Precision management
